SAB Biotherapeutics (SABS) Financials

$3.73

$0.01 (0.27%)

As on 08-Sep-2026 13:31EDT

Market cap

$338 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

15.5

P/B Ratio

1.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	1.32	2.24	23.90	60.88
Cost of Revenue	2.28	3.08	4.79	3.75	3.29	1.65
Gross Profit	-2.28	-3.08	-3.47	-1.51	20.61	59.22
Operating Expenses	69.54	45.87	39.44	36.57	49.53	72.62
Operating Profit (EBIT)	-71.82	-48.95	-42.91	-38.08	-28.92	-13.39
Other Income	--	--	--	--	10.50	-3.46
Profit before Tax	-12.78	13.27	-34.11	-42.19	-18.72	-17.15
Provision for Tax	--	--	--	0.00	0.03	0.30
Profit after Tax (Net Income)	-12.78	13.27	-34.11	-42.19	-18.74	-17.15
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-18.74	-17.14

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	214.79	151.49	25.97	57.30	31.06	38.55
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	11.72	10.63	10.25	15.83	4.85	16.14
Current Liabilities	11.71	10.68	7.98	10.81	14.99	26.46
Total Liabilities	249.92	172.81	44.20	83.94	50.90	81.14

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	130.27	71.76	20.40	25.03	28.81	30.95
Current Assets	107.94	101.05	23.79	58.91	22.10	50.19
Total Assets	249.92	172.81	44.20	83.94	50.90	81.14
Total Debt*	5.13	5.95	4.67	5.91	5.93	8.52
Net Current Assets	96.23	90.37	15.81	48.09	7.10	23.74

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-44.78	-34.29	-25.12	-23.46	1.99
Cash Flow from Investing Activities	--	-121.71	-11.96	-0.15	-2.09	-10.94
Cash from Financing Activities	--	168.30	-1.17	66.77	1.05	35.89
Net Cash Inflow / Outflow	--	--	--	--	-24.50	26.93

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.40	0.28	-3.68	-7.12	-0.37	-3.94
Cash EPS ($)	--	0.34	-3.16	-6.49	-0.34	-3.56
Adjusted Book Value ($)	--	3.18	2.80	9.67	0.62	8.87
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.94	-3.70	-4.24	-0.47	0.46
Free Cash Flow per Share ($)	--	-0.96	-3.74	-4.27	-0.51	-2.06

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	14.11	-72.68	-84.23	-44.59	-36.40
ROE (%)	-6.98	14.96	-81.92	-95.51	-53.85	-44.21
ROA (%)	-8.79	12.23	-53.23	-62.58	-28.39	-24.91
EBIT Margin (%)	--	--	-2,554.95	-1,870.39	-77.03	-27.68
Net Margin (%)	--	--	-2,579.03	-1,884.50	-54.47	-29.86
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	-1.00	-0.41	-0.91	-0.61	0.10
EBIT Growth (%)	65.89	140.00	19.32	-127.42	-9.28	-181.85
Net Profit Growth (%)	65.52	138.92	19.17	-125.14	-9.31	-185.22
EPS Growth (%)	89.87	1.08	0.48	-18.14	0.91	-9.52
Book Value Growth (%)	108.31	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	15.50	13.41	-1.03	-0.10	-1.59	-1.98
Price / Book Value	1.57	1.18	1.35	0.07	0.96	0.88
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	64.16	5.27	-0.66	1.22	-1.36	-0.61
Close Price ($)	3.90	3.74	3.79	6.88	5.90	78.10
High Price ($)	6.60	6.60	7.00	14.50	87.10	129.00
Low Price ($)	1.70	1.00	2.16	3.66	5.01	73.00
Market Cap ($ Cr)	338.47	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.04	0.18	0.10	0.19	0.22
Short term debt to equity ratio	0.00	0.01	0.03	0.03	0.04	0.08
Current Ratio	9.22	9.46	2.98	5.45	1.47	1.90
Quick Ratio	9.22	--	--	--	--	--
Interest Coverage	-54.18	56.15	-106.11	-132.83	-61.06	-57.22

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	4.16	--	23.25	13.16
Asset Turnover	--	--	0.02	0.03	0.36	0.88
Receivable days	--	--	7.59	453.22	103.65	85.74
Inventory Days	--	--	--	--	--	--
Payable days	--	286.87	100.62	225.54	451.44	1,307.40
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.